Scribe Therapeutics Inc. (SCTX) Revenue, Earnings & Financial Statements
$15.77NASDAQ: SCTXMarket Cap $255.19M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Scribe Therapeutics Inc. most recently reported annual revenue of $51.0M, a net loss of $22.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$51.0M
Operating Expenses
$77.0M
Operating Profit
−$26.0M
Operating Margin
-50.9%
Other Income
$2.0M
Interest
$2.0M
Depreciation
$3.0M
Profit Before Tax
−$24.0M
Tax rate (%)
7.6%
Net Profit
−$22.0M
EPS
−$1.24
Quarterly Results — Last 3 Quarters (USD millions)
Metric
Mar '26
Jun '26
Sep '26
Revenue
$2.0M
$2.0M
$2.0M
Operating Expenses
$15.0M
$11.0M
$12.0M
Operating Profit
−$12.0M
−$9.0M
−$11.0M
Operating Margin
-556.5%
-489.8%
-663.9%
Interest
$1.0M
$0
$0
Profit Before Tax
−$17.0M
−$6.0M
−$10.0M
Tax rate (%)
-1.3%
-3.4%
-2.4%
Net Profit
−$17.0M
−$6.0M
−$10.0M
EPS
−$7.05
−$0.37
−$0.52
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$78.0M
Current Assets
$67.0M
Cash
$13.0M
Inventory
$0
Receivables
$7.0M
Fixed Assets
$10.0M
Capital Work in Progress
$0
Investments
$45.0M
Other Assets
$0
Total Liabilities
$101.0M
Current Liabilities
$69.0M
Borrowings
$41.0M
Other Liabilities
$60.0M
Equity
$0
Reserves
−$23.0M
Cash Flow Statement — 1 Years (USD millions)
Metric
2025
Operating Cash Flow
−$45.0M
Investing Cash Flow
$44.0M
Financing Cash Flow
$0
Net Cash Flow
$0
Free Cash Flow
−$46.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-0.02
EV / EBITDA
-3.19
FCF Yield
-5.11%
Quick Ratio
4.72
Interest Coverage
-37.40
Return 1Y
—
Return 3Y
—
Return 5Y
—
Scribe Therapeutics Inc. (SCTX) financials — frequently asked questions
What is Scribe Therapeutics Inc.'s annual revenue?
Scribe Therapeutics Inc. (SCTX) reported annual revenue of $51.0M in its most recent fiscal year.
What is Scribe Therapeutics Inc.'s net profit?
Scribe Therapeutics Inc. (SCTX) reported a net loss of $22.0M in its most recent fiscal year.
What is SCTX EV/EBITDA?
Scribe Therapeutics Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -3.19. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks